Introduction
============

Since 2003, valve implantation has evolved as a new therapy in patients with advanced emphysema.[@b1-copd-11-3093],[@b2-copd-11-3093] Thereby, one-way valves that allow air to exit during expiration but block inspired air are implanted into the bronchi of the most emphysematous lobe, thus leading to lobar volume reduction. By this mechanism, valve therapy minimizes hyperinflation, which impairs functional capacity and influences mortality in patients with COPD.[@b3-copd-11-3093]

The first randomized controlled trials (RCTs) related to valve therapy, known as VENT and Euro-VENT, demonstrated that particularly patients with complete inter-lobar fissure on high-resolution computed tomography (CT) and thus low interlobar collateral ventilation (CV) who had received a complete occlusion of the target lobe experienced relevant clinical improvement.[@b4-copd-11-3093],[@b5-copd-11-3093] Based on this knowledge, only patients who fulfill these prerequisites were enrolled in the following recently published RCT.[@b6-copd-11-3093] In the STELVIO trial, 25 patients with absent CV were treated with valves and compared with 33 patients of a control group.[@b6-copd-11-3093] Efficacy data demonstrated a statistically significant and clinically relevant outcome in the valve group. The adjusted patient selection in comparison to the VENT influenced the spectrum of adverse events and led to a higher rate of complications of which pneumothorax was the most common. In VENT, pneumothorax rate was reported at 4.2%, whereas pneumothorax rate increased up to 18% in STELVIO. In further trials, the authors reported even higher pneumothorax rates of 20%--25%.[@b7-copd-11-3093],[@b8-copd-11-3093] It is likely that a parenchymal rupture of the ipsilateral, untreated lobe due to a rapid expansion because of the volume reduction of the treated lobe is the reason for the occurrence of pneumothorax. Although pneumothorax is a severe complication that may present a life-threatening situation and is associated with prolonged hospitalization, immobilization, and further invasive interventions, it does not appear to have a negative impact on patients' outcome. One retrospective trial evaluated the clinical outcome of 25 patients who developed a pneumothorax following valve placement.[@b9-copd-11-3093] Despite the pneumothorax, patients achieved a substantial lobar volume reduction of 65%±36%, which was associated in most cases with excellent clinical outcomes. However, as the number of patients is very low in this study population, it is not possible to make a general statement on the impact of pneumothorax on clinical outcomes. Therefore, a further retrospective analysis evaluating the impact of pneumothorax on outcome measures following valve placement was performed in order to better assess the influence of this common complication.

Materials and methods
=====================

The database was queried for patients with severe emphysema, who were treated by endoscopic valve therapy between January 2009 and December 2013 at the Thoraxklinik at the University of Heidelberg. In this analysis, clinical outcome measures and radiological outcomes of patients who developed pneumothorax during a follow-up of up to 1 year following valve placement were evaluated. The protocol of this trial was approved by the local ethics committee of the University of Heidelberg (S-609/2012). The majority of the patients were treated within various prospective trials after written informed consent was obtained. As the data in this current analysis were retrospectively analyzed no further patient consent was required.

Subject enrollment
------------------

All patients with severe emphysema who experienced a pneumothorax following the placement of endobronchial valves (Pulmonx, Neuchatel, Switzerland) and/or intrabronchial valves (Olympus Corporation, Tokyo, Japan) into the most emphysematous lobe were enrolled in the analysis. All patients treated with valves suffered from severe emphysema, which had been confirmed in baseline lung function tests demonstrating a significant forced expiratory volume in 1 second (FEV~1~) reduction and severe hyperinflation. Furthermore, each patient had undergone multi-detector CT, including software analysis (yet another CT analyzer, YACTA) and perfusion scan in order to identify the most emphysematous lobe as the target lobe.

Pneumothorax assessment
-----------------------

All pneumothoraces occurring during 1 year following valve placement were recorded. The prevalence, onset, duration, and management of pneumothorax following valve treatment were assessed. In the case of pneumothorax, the subsequent procedure (chest tube insertion, valve removal, video-assisted thoracoscopy or thoracotomy) was dependent on the extent of the pneumothorax and/or clinical symptoms. The treatment algorithm for a post-interventional pneumothorax was derived from the expert statement published in 2014.[@b10-copd-11-3093] In brief, the first step in symptomatic or large pneumothorax is the immediate insertion of a chest tube. In case of an ongoing air leak for \>7 days or in case of a lack of full lung re-expansion, the removal of one valve should be considered in order to inflate the target lobe again and thus re-establish pleural contact. If the air leak continues or no re-expansion is achieved, all valves should be removed. If these interventions remain unsuccessful, pleurodesis or surgical intervention needs to be considered. In summary, the pneumothorax management can vary depending on the clinical signs, the amount of air leak, and the existence of soft tissue emphysema.

Assessment of clinical data
---------------------------

The data were collected by reviewing medical reports and radiological imaging. Lung function parameters (vital capacity \[VC\], FEV~1~, residual volume \[RV\], total lung capacity \[TLC\]), exercise test (6-minute walk test \[6-MWT\]), and dyspnea score (modified Medical Research Council \[mMRC\]) were collected from each patient prior to valve placement and 3 months after recovering from pneumothorax. For each patient, all chest X-rays and CT scans taken following the valve therapy were reviewed. The patients were divided into two subgroups depending on whether a complete lobar atelectasis could be observed. The patients with complete lobar atelectasis as the maximum radiological result following valve placement belonged to the atelectasis group, whereas the other subgroup consisted of patients with partial atelectasis, dystelectasis or no change in volume.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS Statistics (IBM SPSS Statistics for Windows, Version 22.0; IBM Corporation, Armonk, NY, USA). Data are presented as mean ± standard deviation, minimum and maximum, or n and % for frequency data. Changes from baseline to follow-up in lung function, exercise capacity, and mMRC were expressed by descriptive statistics (mean, range, standard deviation). Statistical comparison for the pre-interventional baseline examinations versus follow-up examinations was made using the paired two-sided *t*-test. Missing data were imputed by an additional multivariate imputation on the basis of the patients' baseline values. *P*-values \<0.05 was considered as statistically significant.

Results
=======

From January 2009 to December 2013, 381 patients with severe emphysema received endoscopic valve therapy. The mean age was 64 years (range: 41--81 years), and 52% of them were males. The mean FEV~1~ was 0.8 L and the mean RV was 262%±21% predicted ([Table 1](#t1-copd-11-3093){ref-type="table"}). The left lower lobe was the most common target lobe ([Table 2](#t2-copd-11-3093){ref-type="table"}).

Overall, 18% (70/381) of the patients developed a pneumothorax as a complication following valve implantation ([Figure 1](#f1-copd-11-3093){ref-type="fig"}). In 51 out of 65 patients (79%), pneumothorax occurred within the first 3 days following intervention (median time to pneumothorax was 1 day \[range: 0--125 days\]). In the remaining five patients, pneumothorax onset and duration were unknown, as these patients developed pneumothorax outside the hospital and were referred to other centers.

In 13% (9/70) of the patients, pneumothorax resolved under careful observation. In 87% (61/70) of the patients, chest tube insertion was necessary. In 51% (31/61) of these patients, chest drain insertion did not lead to the resolution of pneumothorax, so valve removal was required. Despite chest tube drainage and valve removal, a persistent fistula was observed in 45% (14/31) of the patients, necessitating a talc slurry in one patient and additional surgical interventions in 13 patients (video-assisted thoracoscopy 77% \[10/13\], thoracotomy 15% \[2/13\] or both 8% \[1/13\]). During the first 3 months after valve explantation, 5 of the 31 patients in whom valve removal had been performed underwent reimplantation of the valve to achieve a lobar occlusion again.

Three months after recovering from pneumothorax, the patients experienced a modest improvement in lung function parameters, 6-MWT and mMRC ([Table 3](#t3-copd-11-3093){ref-type="table"}).

In 60% of the patients with pneumothorax (42/70), no complete lobar atelectasis was observed at any time. However, these patients did show a statistically significant improvement in RV (%) and TLC (%; [Table 4](#t4-copd-11-3093){ref-type="table"}). Thirty-two percent (11/34) of these patients met the efficacy threshold of \>100 mL improvement in FEV~1~, and 54% (14/26) of the patients experienced a 6-MWT improvement of \>26±2 m.[@b11-copd-11-3093],[@b12-copd-11-3093] Fifteen percent (5/34) of the patients experienced an FEV~1~ worsening of \>100 mL and 31% (8/26) developed a decrease in the 6-MWT of \>26±2 m ([Figure 2A and B](#f2-copd-11-3093){ref-type="fig"}).

In 40% (28/70) of all pneumothorax patients, a lobar atelectasis was observed radiologically. In 64% (16/28) of the patients, atelectasis was confirmed after recovering from pneumothorax, and in 36% (12/28) of the patients, atelectasis was confirmed prior/during pneumothorax. Three months following pneumothorax, valve therapy was associated with significant improvement in all lung function parameters except VC ([Table 5](#t5-copd-11-3093){ref-type="table"}). Forty-two percent (8/19) of the patients met the efficacy threshold of \>100 mL improvement in FEV~1~, and 56% (9/16) of the patients experienced a 6-MWT improvement of \>26±2 m. In 5% (1/19) of the patients, an FEV~1~ worsening of \>100 mL and in 25% (4/16) of the patients, a decrease in the 6-MWT of \>26±2 m could be observed ([Figure 2A and B](#f2-copd-11-3093){ref-type="fig"}). In 54% (15/28) of the patients, atelectasis was still confirmed 3 months after recovering from pneumothorax. Regarding only these 15 patients with persistent lobar atelectasis 3 months after recovering from pneumothorax, great improvements were observed (ΔVC: 299±463 mL, ΔVC: 11.7%±15% predicted, ΔFEV~1~: 122±143 mL, ΔFEV~1~: 5.1%±5.4% predicted, ΔRV: −995±744 mL, ΔRV: −43.8%±33.9% predicted, ΔTLC: −653±573 mL, ΔTLC: −10.7%±9.1% predicted, Δ6-MWT: 22.8 m±56.8 m, ΔmMRC: −0.8±1.6 points).

Discussion
==========

Efficacy of endoscopic valve therapy in patients with severe emphysema and low CV was demonstrated in various different RCTs.[@b5-copd-11-3093],[@b6-copd-11-3093],[@b13-copd-11-3093] Although valve placement is a minimally invasive therapeutic approach, it is associated with complications of which pneumothorax is the most common. In this analysis, the pneumothorax rate of 18% was comparable with the rates of 18%--25% reported in other trials.[@b6-copd-11-3093]--[@b8-copd-11-3093] Regarding the management of pneumothorax, 87% of patients had to undergo chest tube insertion. A comparably high rate of chest drainage of 83% could also be seen in the recently published STELVIO trial.[@b6-copd-11-3093] The rates of necessary valve explantation of 44% in the current analysis and 50% in the STELVIO were also similar.

In 78% of the patients, the pneumothorax occurred during the first 3 days following valve placement, so that a hospital stay for 48--72 hours for surveillance should be recommended routinely.[@b10-copd-11-3093] In 22% of the patients, however, pneumothorax occurred after hospital discharge. Therefore, it is of great importance to inform the patients of the symptoms of pneumothorax and explain to them to seek medical help quickly.

One retrospective analysis published in 2014 based on the data of 25 patients with pneumothorax following valve implantation revealed that the patients will nevertheless experience a good outcome with a target lobe volume reduction of 65%±36% following valve implantation.[@b4-copd-11-3093],[@b5-copd-11-3093],[@b9-copd-11-3093],[@b14-copd-11-3093] The current analysis of 70 patients with pneumothorax also confirms that a pneumothorax generally has no negative impact on the clinical status. Thereby, mainly patients in whom lobar atelectasis occurred despite pneumothorax will experience a clinically relevant improvement in lung function parameters. The abscence of mean improvement of exercise capacity measured by the 6-MWT, despite the statistically significant improvement in lung function parameters, may result from the prolonged immobilization and the subsequent muscle wasting.[@b15-copd-11-3093] The patients without a significant TLVR -- which represents the majority of all pneumothorax patients -- experienced only a slight mean improvement in lung function parameters. Overall, 36% (19/53) and 55% (23/42) of all pneumothorax patients met the responder criteria for FEV~1~ and the 6-MWT, respectively. In 11% (6/53) and 29% (12/42) of the patients, a clinically significant worsening of FEV~1~ and 6-MWT was observed, respectively.

Overall, a great variability in the clinical outcome following valve therapy was observed in the total patient cohort. Another retrospective analysis demonstrated that in patients who develop lobar atelectasis following valve therapy, the changes in lung function parameters, exercise capacity, and dyspnea score depend on different variables, such as the emphysema score of the treated lobe, 6-MWT, VC, and RV at baseline.[@b16-copd-11-3093] It can be assumed that the outcomes following pneumothorax are also influenced by various baseline parameters, resulting in such a great variability.

One explanation for the missing target lobe volume reduction in the majority of patients is the necessity for valve removal because of the pneumothorax. In 44% of all pneumothorax patients, valve removal was necessary due to persistent collapse of the lung despite chest tube insertion. These patients will not benefit significantly from valve therapy as only a complete occlusion of one lung lobe is associated with a good outcome.[@b17-copd-11-3093] Another explanation may be valve dislocation or dysfunction due to movement of lung parenchyma and bronchi in case of pneumothorax also resulting in a lack of target lobe volume reduction.

Efficacy data showed that pneumothorax is not associated with a clinically relevant improvement in the majority of patients, but it impairs the clinical status only in a minority. Therefore, the relatively high risk of pneumothorax is accepted by most physicians and patients. Nevertheless, the evaluation of pneumothorax predictors to find a balance between efficacy and safety and the evaluation of a prevention strategy of pneumothorax are crucial to minimize this anticipated adverse event of endoscopic lung volume reduction in emphysema patients. In one retrospective analysis, various CT parameters and clinical variables were found to be significant predictors of pneumothorax.[@b18-copd-11-3093] These findings, however, will have to be confirmed in a prospective study.

Another retrospective trial evaluating a strategy to prevent pneumothorax found a reduction in risk by maintaining a 48-hour bed rest and the prescription of an antitussive therapy following valve placement. However, the number of treated patients in this analysis was too low to allow a general statement for or against this modified post-interventional strategy.[@b7-copd-11-3093]

Conclusion
==========

In summary, pneumothorax is a frequent complication following endoscopic valve therapy in emphysema patients. Although pneumothorax does not impair the clinical status in the majority of patients during follow-up, this complication needs to be considered a serious adverse event and an emergency in patients with advanced emphysema and limited respiratory reserve. Adequate pneumothorax management, including chest tube insertion, valve removal, or surgical interventions, should be available in any institution performing endoscopic valve therapy. Further research evaluating pneumothorax predictors and prevention strategies are crucial to balance the risk--benefit ratio for patients undergoing endoscopic valve therapy.
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![Multi-detector CT.\
**Note:** Chest tube insertion because of pneumothorax following valve placement in the left upper lobe.\
**Abbreviation:** CT, computed tomography.](copd-11-3093Fig1){#f1-copd-11-3093}

![Response rate for FEV~1~ and 6-MWT.\
**Notes:** (**A**) A bar chart showing the response rate for FEV~1~ change with a bar for each unique individual patient (n=53). Light gray denotes no atelectasis at any time. Dark gray denotes evidence of atelectasis at any time point. Dark gray/dotted represents persistent atelectasis. MCID threshold: improved, FEV~1~ \>100 mL; declined, FEV~1~ \>−100 mL. (**B**) A bar chart showing response rate for 6-MWT change with a bar for each unique individual patient (n=42). Light gray denotes no atelectasis at any time. Dark gray denotes evidence of atelectasis at any time point. Dark gray/dotted represents persistent atelectasis. MCID threshold: improved, 6-MWT \>26±2 m; declined, 6-MWT \>−26±2 m.\
**Abbreviations:** FEV~1~, forced expiratory volume in 1 second; MCID, minimal clinically important difference; 6-MWT, 6-minute walk test.](copd-11-3093Fig2){#f2-copd-11-3093}

###### 

Baseline characteristics of all patients treated by valves

  Baseline clinical measures   n     Mean ± SD     Min     Max
  ---------------------------- ----- ------------- ------- -------
  VC (L)                       381   2.4±0.65      0.6     4.9
  VC (% predicted)             378   69.2±12.37    21      118.7
  FEV~1~ (L)                   381   0.8±0         0.3     2.1
  FEV~1~ (% predicted)         380   30.1±0.92     11.7    74.2
  RV (L)                       379   5.7±0.35      3.1     9.2
  RV (% predicted)             380   261.7±21.4    143.5   523
  TLC (L)                      378   8.7±1.01      5.1     243.1
  TLC (% predicted)            380   139.2±12.7    89.9    232
  6-MWT (m)                    343   272.3±110.3   30      490
  mMRC (points)                309   2.8±1.4       0       4

**Abbreviations:** SD, standard deviation; VC, vital capacity; FEV~1~, forced expiratory volume in 1 second; RV, residual volume; TLC, total lung capacity; 6-MWT, 6-minute walk test; mMRC, modified Medical Research Council; Min, minimum; Max, maximum.

###### 

Distribution of treated target lobe

  Target lung area               Target lobe of valve placement (n=381)   Advent of pneumothorax related to target lobe (n=70)        
  ------------------------------ ---------------------------------------- ------------------------------------------------------ ---- ------
  Right upper lobe               46                                       12                                                     7    15.2
  Right upper lobe/middle lobe   39                                       10.5                                                   2    5.1
  Middle lobe                    1                                        0.3                                                    0    0
  Right lower lobe               54                                       14.1                                                   8    14.8
  Right lower lobe/middle lobe   1                                        0.3                                                    0    0
  Segment 6 right                1                                        0.3                                                    0    0
  Left upper lobe                83                                       21.7                                                   25   30.1
  Left lower lobe                155                                      40.6                                                   28   18.1
  Upper lobes bilateral          1                                        0.3                                                    0    0

###### 

Clinical outcome of all patients 3 months recovering after pneumothorax

  Clinical outcome measures   All patients with pneumothorax (n=70; baseline--3 months following pneumothorax)                
  --------------------------- ---------------------------------------------------------------------------------- ------------ ----------------------------------------------------
  ΔVC (mL)                    53                                                                                 28±494       0.676
  ΔVC (% predicted)           53                                                                                 1.7±14.7     0.414
  ΔFEV~1~ (mL)                53                                                                                 55±148       0.009
  ΔFEV~1~ (% predicted)       53                                                                                 2.0±5.3      0.007
  ΔRV (mL)                    50                                                                                 −390±964     0.006
  ΔRV (% predicted)           50                                                                                 −23.0±43.3   0.001[\*](#tfn2-copd-11-3093){ref-type="table-fn"}
  ΔTLC (mL)                   51                                                                                 −348±876     0.007
  ΔTLC (% predicted)          51                                                                                 −7.1±15.8    0.002
  Δ6-MWT (m)                  42                                                                                 13.9±72.9    0.223
  ΔmMRC (points)              38                                                                                 −0.2±1.3     0.400

**Note:**

Imputation analysis revealed statistical significance.

**Abbreviations:** SD, standard deviation; VC, vital capacity; FEV~1~, forced expiratory volume in 1 second; RV, residual volume; TLC, total lung capacity; 6-MWT, 6-minute walk test; mMRC, modified Medical Research Council.

###### 

Clinical outcome of all patients with pneumothorax but without lobar atelectasis 3 months after recovering from pneumothorax

  Clinical outcome measures   All patients with pneumothorax, but without atelectasis (n =48; baseline--3 months following pneumothorax)                
  --------------------------- ------------------------------------------------------------------------------------------------------------ ------------ -------
  ΔVC (mL)                    34                                                                                                           −51±493      0.598
  ΔVC (% predicted)           34                                                                                                           −1.1±14.1    0.449
  ΔFEV~1~ (mL)                34                                                                                                           39±142       0.115
  ΔFEV~1~ (% predicted)       34                                                                                                           1.3±4.9      0.119
  ΔRV (mL)                    32                                                                                                           −203±835     0.179
  ΔRV (% predicted)           32                                                                                                           −15.9±34.0   0.013
  ΔTLC (mL)                   32                                                                                                           −237±805     0.107
  ΔTLC (% predicted)          32                                                                                                           5.1±12.8     0.032
  Δ6-MWT (m)                  26                                                                                                           15.4±75.5    0.308
  ΔmMRC (points)              24                                                                                                           −0.4±1.0     0.846

**Abbreviations:** SD, standard deviation; VC, vital capacity; FEV~1~, forced expiratory volume in 1 second; RV, residual volume; TLC, total lung capacity; 6-MWT, 6-minute walk test; mMRC, modified Medical Research Council.

###### 

Clinical outcome 3 months after recovering from pneumothorax of all patients with pneumothorax and lobar atelectasis

  Clinical outcome measures   All patients with pneumothorax and atelectasis (prior/during and following pneumothorax; n =28; baseline--3 months following pneumothorax)                
  --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------- ------------ ----------------------------------------------------
  ΔVC (mL)                    19                                                                                                                                           170±475      0.136
  ΔVC (% predicted)           18                                                                                                                                           6.9±14.7     0.062
  ΔFEV~1~ (mL)                19                                                                                                                                           82±158       0.036
  ΔFEV~1~ (% predicted)       19                                                                                                                                           3.3±5.8      0.023[\*](#tfn5-copd-11-3093){ref-type="table-fn"}
  ΔRV (mL)                    18                                                                                                                                           −721±1.107   0.013
  ΔRV (% predicted)           19                                                                                                                                           −35.1±54.5   0.012
  ΔTLC (mL)                   18                                                                                                                                           −547±983     0.030
  ΔTLC (% predicted)          19                                                                                                                                           −10.5±19.9   0.034
  Δ6-MWT (m)                  16                                                                                                                                           11.5±70.9    0.526
  ΔmMRC (points)              14                                                                                                                                           −0.4±1.7     0.374

**Note:**

Imputation analysis revealed statistical significance.

**Abbreviations:** SD, standard deviation; VC, vital capacity; FEV~1~, forced expiratory volume in 1 second; RV, residual volume; TLC, total lung capacity; 6-MWT, 6-minute walk test; mMRC, modified Medical Research Council.
